New: Introducing the Finviz Crypto Map

Learn More
Last Close
Jul 17 12:46PM ET
2.03
Dollar change
+0.01
Percentage change
0.25
%
IndexRUT P/E- EPS (ttm)-0.06 Insider Own0.95% Shs Outstand152.43M Perf Week-8.78%
Market Cap308.94M Forward P/E30.37 EPS next Y0.07 Insider Trans0.00% Shs Float151.11M Perf Month-0.25%
Enterprise Value435.52M PEG- EPS next Q-0.01 Inst Own82.20% Short Float24.44% Perf Quarter5.47%
Income-7.79M P/S2.08 EPS this Y80.56% Inst Trans12.40% Short Ratio23.58 Perf Half Y37.76%
Sales148.52M P/B- EPS next Y480.95% ROA-3.43% Short Interest36.92M Perf YTD32.35%
Book/sh-0.19 P/C6.10 EPS next 5Y- ROE- 52W High3.73 -45.71% Perf Year-38.82%
Cash/sh0.33 P/FCF- EPS past 3/5Y65.87% 48.68% ROIC-5.31% 52W Low1.04 94.71% Perf 3Y-34.47%
Dividend Est.- EV/EBITDA- Sales past 3/5Y18.67% -0.23% Gross Margin73.97% Volatility4.14% 5.70% Perf 5Y-87.15%
Dividend TTM- EV/Sales2.93 EPS Y/Y TTM91.67% Oper. Margin-2.41% ATR (14)0.11 Perf 10Y-93.29%
Dividend Ex-Date- Quick Ratio1.76 Sales Y/Y TTM12.43% Profit Margin-5.24% RSI (14)43.95 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.40 EPS Q/Q164.11% SMA20-4.67% Beta1.17 Target Price6.25
Payout- Debt/Eq- Sales Q/Q12.21% SMA50-0.87% Rel Volume0.51 Prev Close2.02
Employees122 LT Debt/Eq- EarningsMay 06 BMO SMA2007.58% Avg Volume1.57M Price2.03
IPOAug 26, 1987 Option/ShortYes / Yes EPS/Sales Surpr.261.29% 3.93% Trades Volume420,682 Change0.25%
Date Action Analyst Rating Change Price Target Change
Jun-09-25Initiated H.C. Wainwright Buy $6
Jun-13-24Initiated Rodman & Renshaw Buy $7
Apr-23-24Initiated CapitalOne Overweight $6
Mar-13-24Reiterated Needham Buy $4 → $5
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jul-07-25 08:50AM
Jul-04-25 08:50AM
May-07-25 03:38PM
03:04AM
May-06-25 09:30AM
08:55AM Loading…
08:55AM
07:53AM
07:45AM
07:30AM
May-05-25 10:33AM
May-01-25 10:01AM
Apr-29-25 10:01AM
Apr-28-25 06:55PM
Apr-24-25 08:56AM
Apr-23-25 09:32AM
08:50AM Loading…
08:50AM
Apr-22-25 04:05PM
10:15AM
09:40AM
07:24AM
Mar-26-25 03:57PM
Feb-28-25 02:08AM
12:56AM
Feb-27-25 09:30AM
07:54AM
07:45AM
Feb-13-25 04:20PM
Dec-23-24 04:05PM
Dec-03-24 04:36PM
Nov-13-24 02:05AM
10:00AM Loading…
Nov-12-24 10:00AM
09:10AM
08:06AM
07:55AM
Nov-07-24 09:15AM
Nov-04-24 05:00PM
Oct-29-24 04:05PM
Oct-10-24 04:08PM
Sep-25-24 08:00AM
Sep-03-24 08:00AM
Aug-06-24 07:30PM
06:45PM
05:36PM
04:05PM
Jul-30-24 04:05PM
Jul-15-24 08:00AM
Jul-11-24 12:00PM
Jul-02-24 08:00AM
May-29-24 08:05AM
May-21-24 12:00PM
May-08-24 12:30PM
03:10AM
May-07-24 12:54PM
09:34AM
09:30AM
09:05AM
08:06AM
08:00AM
Apr-30-24 10:01AM
Apr-24-24 08:00AM
Apr-11-24 04:05PM
Mar-28-24 04:05PM
Mar-13-24 09:19AM
07:04AM
Mar-12-24 06:00PM
05:33PM
04:34PM
04:05PM
Mar-07-24 09:15AM
Feb-28-24 08:00AM
Feb-23-24 11:56AM
Feb-06-24 12:00PM
Jan-25-24 06:44AM
Jan-24-24 01:47PM
Jan-23-24 08:00PM
Jan-15-24 04:51PM
09:55AM
Jan-07-24 05:00PM
Dec-10-23 12:23PM
Dec-06-23 11:55AM
Nov-28-23 07:33PM
Nov-15-23 10:17AM
08:51AM
08:46AM
Nov-14-23 06:00PM
04:17PM
04:05PM
Nov-07-23 04:05PM
Aug-24-23 09:29AM
Aug-15-23 01:30PM
12:48PM
09:47AM
Aug-14-23 04:29PM
04:05PM
Aug-07-23 04:05PM
10:50AM
Jul-26-23 01:30PM
Jul-24-23 09:02AM
09:00AM
Jun-23-23 04:05PM
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.
Last Close
Jul 17 12:46PM ET
1.71
Dollar change
+0.05
Percentage change
2.71
%
GOSS Gossamer Bio Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.24 Insider Own19.64% Shs Outstand227.22M Perf Week25.37%
Market Cap387.55M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float182.66M Perf Month33.20%
Enterprise Value332.41M PEG- EPS next Q-0.18 Inst Own58.38% Short Float9.26% Perf Quarter105.45%
Income-51.24M P/S3.11 EPS this Y-169.82% Inst Trans0.59% Short Ratio8.49 Perf Half Y100.97%
Sales124.59M P/B- EPS next Y31.68% ROA-18.98% Short Interest16.91M Perf YTD88.48%
Book/sh-0.03 P/C1.50 EPS next 5Y19.90% ROE-500.57% 52W High1.70 0.29% Perf Year44.49%
Cash/sh1.13 P/FCF- EPS past 3/5Y56.92% 40.29% ROIC-26.18% 52W Low0.66 157.67% Perf 3Y-76.35%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin97.20% Volatility9.18% 8.00% Perf 5Y-86.97%
Dividend TTM- EV/Sales2.67 EPS Y/Y TTM78.54% Oper. Margin-43.96% ATR (14)0.11 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.71 Sales Y/Y TTM- Profit Margin-41.13% RSI (14)73.03 Recom1.40
Dividend Gr. 3/5Y- - Current Ratio5.71 EPS Q/Q13.03% SMA2025.07% Beta1.91 Target Price8.03
Payout- Debt/Eq- Sales Q/Q- SMA5036.63% Rel Volume2.59 Prev Close1.66
Employees145 LT Debt/Eq- EarningsMay 15 AMC SMA20062.07% Avg Volume1.99M Price1.71
IPOFeb 08, 2019 Option/ShortYes / Yes EPS/Sales Surpr.14.48% 143.13% Trades Volume2,723,330 Change2.71%
Date Action Analyst Rating Change Price Target Change
Jul-14-25Initiated Scotiabank Sector Outperform $11
Jun-25-24Initiated Oppenheimer Outperform $9
Apr-05-24Resumed Wedbush Outperform $4
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Jun-24-25 12:46PM
Jun-16-25 07:31AM
Jun-06-25 05:30PM
May-21-25 07:00AM
May-16-25 09:11AM
03:15AM Loading…
03:15AM
May-15-25 05:15PM
04:09PM
04:01PM
May-14-25 09:45AM
May-12-25 04:01PM
May-07-25 05:30PM
04:01PM
May-02-25 01:21PM
Apr-16-25 09:57AM
09:44AM Loading…
Apr-09-25 09:44AM
Apr-08-25 05:30PM
Mar-27-25 09:45AM
Mar-26-25 01:38PM
Mar-23-25 08:41AM
Mar-13-25 05:10PM
04:06PM
04:01PM
Mar-07-25 05:30PM
Feb-19-25 06:00AM
Feb-07-25 05:30PM
Feb-03-25 07:01AM
Jan-28-25 07:01AM
Jan-07-25 05:30PM
09:19AM
12:00PM Loading…
Dec-26-24 12:00PM
Nov-21-24 12:00PM
Nov-15-24 09:35AM
Nov-14-24 09:35AM
Nov-11-24 04:01PM
Nov-07-24 06:00PM
04:59PM
04:03PM
Oct-31-24 07:00AM
Oct-30-24 07:00AM
Oct-29-24 07:00AM
Oct-07-24 05:01PM
Sep-25-24 07:00AM
Sep-24-24 07:00AM
Aug-26-24 04:01PM
Aug-21-24 07:00AM
Aug-20-24 07:00AM
Aug-12-24 10:53PM
05:10PM
04:15PM
04:01PM
Jul-25-24 02:35AM
Jun-13-24 03:35PM
Jun-07-24 04:30PM
May-14-24 04:01PM
May-10-24 04:30PM
May-07-24 10:56PM
05:15PM
04:01PM
05:11AM
04:31AM
May-06-24 03:17PM
08:17AM
08:11AM
07:41AM
07:30AM
May-03-24 08:02AM
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.